MSD has reported that the Phase III ZENITH trial of WINREVAIR for pulmonary arterial hypertension met its primary endpoint.

AstraZeneca has reported positive results from a Phase III trial that evaluated Truqap combined with abiraterone and ADT for ...

Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.

ArkBio has concluded enrolment and dosing for a Phase I trial of AK0610, to prevent RSV infection, particularly in vulnerable ...

Cybersecurity is another critical issue, as health data is particularly vulnerable to breaches, which can lead to identity ...

The biopharmaceutical industry is being called to take its sustainability efforts to the next level. A new report sheds light ...

The company’s oral, microbiome-changing therapy was well tolerated in patients with amyotrophic lateral sclerosis.

Adaptive designs are becoming more popular, speeding up trial processes by offering a higher degree of flexibility. Credit: PeopleImages.com – Yuri A / Shutterstock. A report by Novotech has ...

The Global Coalition for Adaptive Research (GCAR) has executed an agreement to evaluate AstraZeneca's AZD1390 in the GBM ...

SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous HBV)-specific TCR-T therapy, ...

The BioInteliSense study, which was conducted over 15 months in the medical-surgical units of two US hospitals, utilised the company’s multi-parameter continuous monitoring device which is placed on ...

Dubbed Nubeqa but known generically as darolutamide, the treatment comes in combination with androgen deprivation therapy ...